NVS Stock Recent News
NVS LATEST HEADLINES
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Switzerland's COMCO competition commission terminated an investigation against Novartis into possibly using blocking patents, without consequences, it said on Thursday.
Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock, with strong profitability and manageable debt. Despite some declining revenues from established brands, Novartis' pipeline and recent performance suggest continued growth, with double-digit revenue and income growth expected in 2024. The company lacks a "mega-blockbuster" drug but has a solid portfolio and potential for strategic acquisitions to enhance its pipeline.
SOMERVILLE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate's proprietary generative AI platform, “The Generate Platform,” to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation. The collaboration will combine The Generate Platform, which integrates.
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with the secondary effects of weight loss, but that it does not plan to compete directly with Novo Nordisk and Eli Lilly.
Vas Narasimhan, CEO of Novartis, says the pharmaceutical company does not plan to follow competitors in entering into the weight loss drugs market.
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1 ,2 Kisqali ® (ribociclib) significantly reduced the risk of recurrence by 25% vs.
American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer success than originally thought.